Released: February 9, 2018

Defense Health Program
Department of Defense Bone Marrow Failure Research Program
Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)

Due to the current Continuing Resolution, the FY18 Defense Appropriations bill has not been passed. Although funds have not been appropriated for the Department of Defense Bone Marrow Failure Research Program (BMFRP), the BMFRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY18 funding opportunities.

FY18 BMFRP Program Announcement and General Application Instructions for the following award mechanism are anticipated to be posted on in April 2018. Pre-application and application deadlines will be available when the Program Announcement is released. This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to this Program Announcement is contingent on the availability of Federal funds appropriated for the BMFRP.

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

Award Mechanism Eligibility Key Mechanism Elements Funding
Idea Development Award Established Investigators:
Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree
Early-Career Investigators:
Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or on family medical leave) at the time of application submission deadline are eligible.
  • Preproposal is required; full application submission is by invitation only.
  • Supports innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the vision to understand and cure bone marrow failure (BMF).
  • Strong BMF research team.
  • May include relevant preliminary data.
  • Clinical trials will not be supported.
  • Maximum funding of $325,000 in direct costs (plus indirect costs)
  • Period of performance not to exceed 2 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at prior to the pre-application deadline. All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the website. The application package containing the required forms for each award mechanism will also be found on website. A listing of all CDMRP funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government’s single-entry portal, website. Submission deadlines are not available until the Program Announcement is released. For email notification when the Program Announcement is released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at For more information about the BMFRP or other CDMRP-administered programs, please visit the CDMRP website (

Point of Contact:

CDMRP Public Affairs

Last updated Thursday, May 26, 2022